Who makes Colonlytely?

Colonlytely is developed by Fremantle Hospital and Health Service.

What development phase is Colonlytely in?

Colonlytely is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Colonlytely

Fremantle Hospital and Health Service · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Colonlytely
Also known as	Polyethylene glycol
Sponsor	Fremantle Hospital and Health Service
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer (PHASE2)
Tolerability, Efficacy and Mucosal Inflammation Associated With Orally Administered Colon Cleansing for Colonoscopy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Colonlytely CI brief — competitive landscape report
Colonlytely updates RSS · CI watch RSS
Fremantle Hospital and Health Service portfolio CI